Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
26. März 2024 08:30 ET
|
Dyadic International, Inc.
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO. ...
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
13. März 2024 07:59 ET
|
AB Science
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE...
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13. März 2024 07:59 ET
|
AB Science
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
16. Oktober 2023 08:11 ET
|
Silo Pharma, Inc.
Human tissue study assessed SPU-21’s efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a...
SciSparc Granted European Patent for its Core Technology
03. Oktober 2023 07:33 ET
|
SciSparc Ltd
The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
Bredis Healthcare Awarded South Korean Government Grant for Advancing Early Diagnosis of Alzheimer's Disease
22. August 2023 02:45 ET
|
Bredis Healthcare Inc.
Bredis Healthcare secures KRW 1.7 billion grant for advancing Alzheimer’s disease diagnosis from South Korean government’s Deep Tech TIPS programNovel platform has demonstrated detection of...
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
01. August 2023 09:00 ET
|
SciSparc Ltd
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
02. Juni 2023 09:00 ET
|
SciSparc Ltd
Tel-Aviv, June 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
AB Science annonce la publication de l’étude clinique pivot de phase 3 avec le masitinib dans la maladie d’Alzheimer dans la revue Alzheimer's Research & Therapy
28. Februar 2023 02:03 ET
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DE L'ETUDE CLINIQUE PIVOT DE PHASE 3 AVEC LE MASITINIB DANS LA MALADIE D'ALZHEIMER DANS LA REVUE ALZHEIMER'S RESEARCH & THERAPY Paris, 28 février 2023, 8h AB...
AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy
28. Februar 2023 02:03 ET
|
AB Science
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN ALZHEIMER'S DISEASE IN THE JOURNAL ALZHEIMER'S RESEARCH & THERAPY Paris, 28 February, 2023, 8am CET ...